National Quality Measures Clearinghouse | Target Population Gender: Male || Search Results

Keyword: none
Target Population Gender: Male (only)
1-11 of 11



1. Prostatectomy: risk-adjusted rate of unplanned readmission following discharge for prostatectomy. 2010 May. NQMC:005393
Canadian Institute for Health Information - Nonprofit Organization. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Prostatectomy: risk-adjusted rate of unplanned readmission following discharge for prostatectomy.

2. Urology: average number of patient days (from the first day after surgery) for all patients having a transurethral resection (TUR) for benign prostatomegaly (excluding patients having other procedures), during the 6 month time period. 2010 Jan. NQMC:005985
Australian Council on Healthcare Standards - Health Care Accreditation Organization. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Urology: average number of patient days (from the first day after surgery) for all patients having a transurethral resection (TUR) for benign prostatomegaly (excluding patients having other procedures), during the 6 month time period.

3. Urology: average operating time (minutes) for all patients undergoing a transurethral resection (TUR) for benign prostatomegaly, during the 6 month time period. 2010 Jan. NQMC:005984
Australian Council on Healthcare Standards - Health Care Accreditation Organization. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Urology: average operating time (minutes) for all patients undergoing a transurethral resection (TUR) for benign prostatomegaly, during the 6 month time period.

4. Urology: percentage of patients having a transurethral resection (TUR) for benign prostatomegaly, who have a blood transfusion (intra-operatively or post-operatively) within the same admission, during the 6 month time period. 2010 Jan. NQMC:005986
Australian Council on Healthcare Standards - Health Care Accreditation Organization. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Urology: percentage of patients having a transurethral resection (TUR) for benign prostatomegaly, who have a blood transfusion (intra-operatively or post-operatively) within the same admission, during the 6 month time period.

5. Urology: percentage of patients having an unplanned readmission within 28 days of discharge following transurethral resection (TUR) for benign prostatomegaly, during the 6 month time period. 2010 Jan. NQMC:005987
Australian Council on Healthcare Standards - Health Care Accreditation Organization. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Urology: percentage of patients having an unplanned readmission within 28 days of discharge following transurethral resection (TUR) for benign prostatomegaly, during the 6 month time period.

6. Prostate cancer: percentage of patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving external beam radiotherapy as primary therapy to the prostate with or without nodal irradiation (no metastases; no salvage therapy) who receive three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT). 2008 Oct. NQMC:003489
American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Prostate cancer: percentage of patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving external beam radiotherapy as primary therapy to the prostate with or without nodal irradiation (no metastases; no salvage therapy) who receive three-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT).

7. Prostate cancer: percentage of patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who received counseling on, at a minimum, the following treatment options for clinically localized disease prior to initiation of treatment: active surveillance, AND interstitial prostate brachytherapy, AND external beam radiotherapy, AND radical prostatectomy. 2008 Oct. NQMC:003487
American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Prostate cancer: percentage of patients, regardless of age, with a diagnosis of clinically localized prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who received counseling on, at a minimum, the following treatment options for clinically localized disease prior to initiation of treatment: active surveillance, AND interstitial prostate brachytherapy, AND external beam radiotherapy, AND radical prostatectomy.

8. Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist). 2008 Oct. NQMC:003488
American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist).

9. Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score prior to initiation of treatment. 2008 Oct. NQMC:003484
American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score prior to initiation of treatment.

10. Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer, at low risk of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer. 2008 Oct. NQMC:003486
American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) Compare Selected : National Quality Measures Clearinghouse | Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer, at low risk of recurrence, receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did <em>not</em> have a bone scan performed at any time since diagnosis of prostate cancer.

11. Prostate cancer: percentage of patients, regardless of age, with a new diagnosis of prostate cancer with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score. 2008 Oct. NQMC:003485
American Urological Association - Medical Specialty Society; Physician Consortium for Performance Improvement® - Clinical Specialty Collaboration. View all measures by the developer(s) : National Quality Measures Clearinghouse | Prostate cancer: percentage of patients, regardless of age, with a new diagnosis of prostate cancer with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score.


FULL-TEXT: open here to see/read/download the guidelines:
National Quality Measures Clearinghouse | Search Results